2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3504 Clinical utility of ig‑NGS‑based ctDNA detection in newly diagnosed DLBCL: A large-scale prospective, multicenter study

Wei LIU, Fei Li, MD, PhD2, Keshu Zhou, PhD3, Changming Dong4, Zhiwei Chen5, Xueli Jiao, MD6, Shunjin Zhang7, Xiaoxia Wang8, Jinghua Wu9, Xiao Liu10, Dehui Zou, MD11, Lu-Gui Qiu, PhD12
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Jiangxi Provincial Key Laboratory of Hematological Diseases, Department of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China
3 Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 Jiangxi Provincial Key Laboratory of Hematological Diseases, Department of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China
6 Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
7 NeoImmune Co., LTD, Shenzhen, China
8 NeoImmune Co., LTD, Shenzhen, China
9 NeoImmune Co., LTD, Shenzhen, China
10 Tsinghua University Shenzhen International Graduate School, Shenzhen, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Diffuse large B-cell lymphoma (DLBCL) exhibits marked clinical heterogeneity. Despite standard frontline immunochemotherapy, 30%–40% of patients suffer from relapse or refractoriness with poor prognosis. Traditional methods for prognostic stratification and efficacy evaluation, such as the International Prognostic Index (IPI) and positron emission computed tomography/ computed tomography (PET/CT), have limited predictive accuracy and several drawbacks. As an emerging non-invasive biomarker, ctDNA has shown potential in prognostic assessment for DLBCL, but its clinical utility requires further validation through large-scale, prospective clinical studies. This study aimed to investigate the clinical value of dynamic monitoring of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) using next-generation sequencing based on immunoglobulin gene rearrangements (Ig-NGS) throughout the treatment course in newly diagnosed DLBCL

Methods: A total of 233 patients were prospectively enrolled across three centers, and 1,613 serial plasma samples were analyzed longitudinally throughout treatment. Plasma samples were collected longitudinally at baseline, on the first day of each treatment cycle, at the end of treatment (EOT), and every 3 months during a 2-year post-treatment follow-up period. ctDNA-MRD was detected using Ig-NGS. Associations of baseline ctDNA levels, serial ctDNA-MRD status, and combined MRD and PET/CT assessments with clinical outcomes, primarily progression-free survival, were evaluated.

Results: Baseline ctDNA levels were significantly positively correlated with conventional tumor burden indicators, including Ann Arbor stage III–IV, IPI score ≥2, B symptoms, elevated LDH, bulky disease (≥7.5 cm), and ≥2 extranodal involvement sites (all P < 0.05). Patients with high baseline ctDNA levels (>3.7 LG/mL) had significantly worse 2-year progression-free survival (PFS) compared with those with low levels (≤3.7 LG/mL) (67.0% vs. 84.2%, P = 0.004). At C2D1, the MRD-negative group had significantly superior 2-year PFS compared with the MRD-positive group (88.0% vs. 62.6%, P = 0.012); similar results were observed at C3D1 (83.1% vs. 55.1%, P = 0.004). The predictive value of early MRD for 2-year PFS was superior to that of interim PET2 (C3D1 MRD: P = 0.004; iPET2: P = 0.093). Combined assessment of C3D1MRD and iPET2 enabled identification of high-risk patients: the MRD+PET+ (double-positive) group exhibited a very high risk of relapse/progression, with a 2-year PFS rate of only 36.0%. End-of-treatment MRD (EOT-MRD) and end-of-treatment PET (EOT-PET) showed comparable predictive value for PFS: the 2-year PFS rates for PET-negative and PET-positive groups were 87.1% and 48.9%, respectively (P < 0.001). The 2-year PFS rates for MRD-negative and MRD-positive groups were 85.1% and 50.0%, respectively (P < 0.001). Combining EOT-MRD with EOT-PET further refined prognostic stratification: the MRD-PET-(double-negative) group had the best prognosis, with a 2-year PFS rate of 87.2%, whereas the MRD+PET+ (double-positive) group had a dismal prognosis, with a 2-year PFS of 0%. Multivariate Cox regression analysis incorporating IPI score, C3D1MRD, iPET2, EOT-PET, and EOT-MRD revealed that EOT-PET positivity (HR=14.03, 95% CI 3.73–52.92, P < 0.001) and EOT-MRD positivity (HR= 6.13, 95% CI 1.95–19.27, P = 0.002) were independent adverse prognostic factors for PFS.

Conclusion: Dynamic monitoring of Ig-NGS-based ctDNA provides significant clinical prognostic value throughout the entire treatment course for DLBCL. Pre-treatment ctDNA levels reflect tumor burden and prognosis. Early dynamic changes of ctDNA can predict treatment failure. The MRD status at the end of treatment refines the assessment of remission and represents an independent predictor of relapse risk. Furthermore, the combined application of MRD and PET enhances the accuracy of risk stratification and prognostic evaluation in DLBCL patients, facilitating more precise personalized treatment and comprehensive disease management.

Wei LIU: No relevant conflicts of interest to declare.